Biotech Catalyst Trading: How Hedge Funds and Insiders Position Around FDA Decisions
BWBiopharmaWatch Research··17 min read
Every biotech investor eventually faces the same question: what do I do when a major catalyst is coming? Do I buy before the data readout and hold through the event? Do I sell into the run-up and take profits? Do I wait until after the news and trade the reaction?
There is no single right answer, but there are frameworks that can help. And the best place to start is by looking at what the professionals do. Biotech-focused hedge funds and company insiders approach catalyst events with discipline, process, and a deep understanding of the science. By studying their behavior, individual investors can make better decisions about how to position around FDA decisions, data readouts, and other binary events.
In this final part of the BiopharmaWatch Biotech Investing Masterclass, we cover everything you need to know about catalyst trading in biotech: what catalysts are and why they matter, how hedge funds position, what insider activity tells you, how to size your positions for binary events, and the mistakes that cost investors the most money.
What Is a Biotech Catalyst and Why Does It Matter?
A catalyst is any event that can cause a significant change in a biotech stock's price. Unlike other sectors where stock prices move gradually based on quarterly earnings, biotech stocks are defined by sharp, event-driven moves. A single catalyst can create more value, or destroy more value, in one day than an entire year of normal trading.
The major types of biotech catalysts
Catalyst
What Happens
Typical Price Impact
Predictability
PDUFA date
FDA announces approval or rejection (CRL)
+50% to +200% on approval. -40% to -80% on CRL.
Date is known months in advance
Phase 3 data readout
Company reports pivotal trial results
+20% to +100% positive. -30% to -70% negative.
Company usually guides timing
Phase 2 data readout
Early efficacy data reported
+15% to +80% positive. -20% to -50% negative.
Often a broad window
Advisory Committee (AdCom)
FDA advisory panel votes on approval
+10% to +50% on positive vote
Date announced 1-2 months ahead
NDA/BLA filing or acceptance
Company files with FDA or FDA accepts filing
+5% to +25%
Company controlled
Conference presentation
Data shown at medical conference
+5% to +30% depending on data
Abstract deadlines are public
Partnership or licensing deal
Large pharma licenses or partners on drug
+10% to +50%
Unpredictable timing
The BiopharmaWatch FDA Calendar tracks all of these catalyst types in one place. You can filter by stage, therapeutic area, or search by ticker to see exactly what is coming up and when.
The PDUFA Run-Up: How Stocks Move Before FDA Decisions
One of the most well-documented patterns in biotech is the "PDUFA run-up." In the weeks leading up to a PDUFA date, biotech stocks tend to move higher as traders and investors build positions ahead of the binary event.
Why the run-up happens
The run-up is driven by several forces at the same time:
Speculative buying. Traders who want to bet on approval start building positions 4 to 8 weeks before the decision date.
Hedge fund accumulation. Professional investors who have done deep diligence and have conviction in the drug quietly accumulate shares over weeks, trying not to push the price up too fast.
Short covering. If the stock had been heavily shorted, some shorts start covering their positions ahead of the binary event to limit their risk, which pushes the price higher.
Momentum traders. Once the stock starts moving up, momentum-based algorithms and traders jump in, accelerating the run-up.
Options activity. Increased call option buying ahead of PDUFA dates can create a "gamma squeeze" effect as market makers hedge their exposure by buying shares.
Anatomy of a typical PDUFA run-up
Timeframe
What Usually Happens
Trading Implication
8 to 6 weeks out
Smart money starts quietly building positions. Volume may tick up slightly.
Best time to enter if you are playing the run-up. Stock is not yet "crowded."
6 to 4 weeks out
The move becomes more noticeable. Media coverage and analyst notes increase.
Run-up is underway. Still time to enter, but risk-reward is less favorable.
The easy money has been made. Entering here means you are paying a premium.
2 weeks to day-of
Stock often consolidates or dips as run-up traders take profits. "Sell the news" dynamic begins.
Dangerous time to enter. Many experienced traders are already selling to run-up buyers.
How to play the run-up
There are two main strategies for the PDUFA run-up:
Strategy 1: Play the run-up and sell before the decision. This approach captures the price appreciation from speculative buying without taking the binary risk of the actual FDA decision. You buy 6 to 8 weeks out and sell 1 to 2 weeks before the PDUFA date. The upside is typically 20% to 40%, and you avoid the possibility of a catastrophic CRL. The downside is that you miss the big move if the drug gets approved.
Strategy 2: Hold through the event. This approach is for investors with deep conviction in the drug based on thorough due diligence. You accept the binary risk because you believe the probability of approval is high enough to justify holding. The potential upside is 50% to 200% on approval, but the downside is 40% to 80% on a CRL. This strategy only makes sense if your due diligence gives you a real edge, not just a gut feeling.
How Hedge Funds Position Around Biotech Catalysts
The biggest biotech hedge funds in the world, names like Baker Brothers, OrbiMed, RA Capital, Perceptive Advisors, and Vivo Capital, approach catalyst events very differently from retail investors. Understanding their approach can help you improve your own.
What the best funds do differently
They start with the science. Before looking at the stock price, chart, or market sentiment, the best biotech funds start by understanding the biology, the mechanism of action, and the clinical data at a level of detail that borders on academic. Many employ PhDs, MDs, and former FDA reviewers specifically for this purpose.
They build positions early. Professional funds do not wait until a week before the PDUFA date to take a position. They start buying months in advance, gradually accumulating shares to minimize market impact. By the time the run-up starts, they are already positioned.
They size positions based on conviction and risk. A fund with moderate conviction might take a 1% to 2% portfolio position. A fund with very high conviction might go to 5% or even 10%. The position size reflects their estimate of the probability-weighted outcome, not just whether they think the drug will be approved.
They diversify across multiple catalysts. Instead of betting everything on one PDUFA date, the best funds spread their capital across 10 to 20 catalyst events per quarter. Even if individual events are binary, the portfolio-level outcome is much smoother.
They have exit plans. Before entering a position, professional funds define exactly when and why they would sell. They set stop losses on the science, not just the price. If new information changes the thesis, they exit regardless of whether the stock is up or down.
How to track hedge fund positioning
You can track hedge fund biotech positions through two main sources:
13F filings. Every institutional investor managing more than $100 million must file a 13F with the SEC each quarter, disclosing their equity holdings. The limitation is that 13F filings are reported 45 days after quarter-end, so the data is delayed.
BiopharmaWatch Hedge Fund Tracker. This tool aggregates 13F data specifically for biotech stocks, so you can quickly see which funds hold which biotech positions, how many shares they own, and whether they have been increasing or decreasing their holdings. It is one of the fastest ways to see the smart money picture for any biotech stock.
Insider transactions are one of the most underestimated sources of information in biotech investing. Company executives, directors, and officers are required to report their stock purchases and sales to the SEC within two business days. This creates a real-time window into what the people closest to the company think about its prospects.
In most sectors, insider buying is a moderately useful signal. In biotech, it is significantly more valuable because of the information asymmetry. A biotech CEO or Chief Medical Officer has insight into the clinical data, the regulatory interactions, and the commercial strategy that no outside investor can match. When they buy shares with their own money, it tells you something important about their confidence level.
Insider signal strength ranking
Signal
Strength
What It Tells You
CEO or CMO cluster buying before a catalyst
Very strong
The people closest to the data are putting their money where their mouth is. Highest conviction signal.
Multiple insiders buying around the same time
Strong
When three or four insiders independently decide to buy, it is unlikely to be coincidence.
Large purchase relative to salary
Strong
An executive buying $500K in shares when they make $800K in salary has real skin in the game.
Board member buying
Moderate
Board members have less visibility into day-to-day operations but still have access to material information.
Small routine purchases
Weak
Some insiders buy small amounts regularly as part of a planned program. Less signal value.
Multiple insiders buy within the same 2 to 4 week window
Purchases happen 1 to 3 months before a major catalyst (data readout or PDUFA date)
The purchase size is large relative to the insider's total compensation
The purchase breaks a pattern (an insider who has never bought before suddenly makes a large purchase)
Position Sizing for Binary Events
Position sizing is arguably the most important skill in biotech catalyst trading, and it is the one most individual investors get wrong. The temptation to put a large portion of your portfolio into a stock ahead of a PDUFA date is strong, especially when the setup looks great. But biotech catalysts are inherently uncertain, and even the best-researched positions can go wrong.
The position sizing framework
Conviction Level
Recommended Position Size
When to Use
Very high conviction (POA 70%+, strong data, multiple hedge funds, insider buying)
3% to 5% of portfolio
Everything in your checklist lines up. You have done deep diligence and the risk-reward is compelling.
High conviction (POA 50-70%, solid data, some institutional interest)
1.5% to 3% of portfolio
Good setup but some uncertainty remains. You are comfortable with the thesis but not all-in.
Moderate conviction (POA 30-50%, mixed signals)
0.5% to 1.5% of portfolio
Interesting opportunity but meaningful risk. Smaller position so a loss does not damage the portfolio.
Speculative (POA below 30%, early stage, limited data)
0.25% to 0.5% of portfolio
Lottery ticket positions. You can afford to lose the entire amount without material portfolio impact.
The math behind position sizing
Here is a simple way to think about it. Say you have $100,000 invested in biotech. You are looking at a stock with a PDUFA date coming up. You estimate a 60% chance of approval with 80% upside, and a 40% chance of a CRL with 60% downside.
Expected value of the trade: (0.60 x 0.80) + (0.40 x -0.60) = 0.48 - 0.24 = +24% expected return.
That is a positive expected value trade. But if you put $50,000 (50% of your portfolio) into it and the drug gets rejected, you lose $30,000 in a single day. Can you handle that? Does your portfolio survive that hit?
If instead you put $3,000 (3% of your portfolio) into it and the drug gets rejected, you lose $1,800. That stings, but it does not change your life. And if the drug gets approved, you make $2,400. Across many such positions over a year, the math works in your favor.
The key principle is: size your position so that you can be wrong and still stay in the game. Professional biotech investors expect to be wrong at least 30% to 40% of the time. They survive by making sure no single loss can kill the portfolio.
Common Mistakes in Biotech Catalyst Trading
After watching biotech investors for years, these are the mistakes that come up again and again:
Mistake 1: Buying the day before a PDUFA date. By this point, the run-up has already happened. You are buying at the highest point of speculation and getting the worst possible risk-reward. If the drug gets approved, the stock might go up 30% from where you bought. If it gets rejected, you lose 60%. That is terrible math.
Mistake 2: Oversizing binary positions. Putting 20% or 30% of your portfolio into a single PDUFA event is not investing, it is gambling. Even if you are right 70% of the time, the 30% you are wrong will eventually wipe out your gains. The Kelly Criterion, a well-known position sizing formula, would never recommend that kind of allocation for a binary event.
Mistake 3: Ignoring the science and trading the chart. Technical analysis can be useful for timing entries and exits, but in biotech, the fundamental driver is the science. A stock that looks "overbought" on the chart can still double if the Phase 3 data is strong. A stock with a "bullish setup" on the chart can still crash 60% if the drug fails. Always start with the science.
Mistake 4: Anchor bias after a loss. After a stock drops 50% on a failed trial, many investors hold on hoping it will "come back." In biotech, it usually does not. When the science fails, the thesis is broken. Cut your losses and reallocate the capital to a better opportunity.
Mistake 5: Not having a plan for both outcomes. Before any catalyst, you should know exactly what you will do if the result is positive and what you will do if it is negative. Will you take partial profits on approval? Will you add on a pullback? Will you exit completely on a CRL? Making these decisions under pressure, after hours, while the stock is moving, leads to emotional and often wrong choices.
Mistake 6: Neglecting post-catalyst analysis. Even after an approval, the stock does not always keep going up. Commercial execution, pricing, competition, and label restrictions all matter. Always re-evaluate after a catalyst, even when the outcome is positive.
Using the BiopharmaWatch Tools for Catalyst Trading
The entire BiopharmaWatch platform is designed to give biotech investors the data they need to make informed catalyst trading decisions. Here is how to use each tool:
FDA Calendar is your starting point. Search by ticker or browse the full calendar to see every upcoming PDUFA date, data readout, and advisory committee meeting. Each event includes a Probability of Approval (POA) score, the development stage, therapeutic area, and a link to more information. Use this to build your watchlist and plan your catalyst calendar for the quarter.
Hedge Fund Tracker shows you the institutional ownership picture for any biotech stock. See which funds are holding, how large their positions are, and whether they have been adding or trimming. When three or four top-tier biotech funds converge on the same stock ahead of a catalyst, it is a signal worth paying attention to.
The combination of these tools gives you a workflow: find the catalyst on the FDA Calendar, check the POA, look at what the hedge funds and insiders are doing, apply your due diligence checklist from Part 3, read the clinical data using the framework from Part 2, and then decide whether and how much to invest.
Frequently Asked Questions
What is biotech catalyst trading?
Biotech catalyst trading is a strategy that focuses on buying or selling biotech stocks around major events like FDA approval decisions (PDUFA dates), clinical trial data readouts, and advisory committee meetings. These events are "catalysts" because they can cause significant stock price movements in a single day, often 30% to 100% or more in either direction.
What is the PDUFA run-up?
The PDUFA run-up is a pattern where biotech stocks tend to increase in price in the 4 to 8 weeks leading up to an FDA decision date. This happens because investors and traders build positions ahead of the binary event, creating buying pressure. The run-up typically adds 20% to 40% to a stock's price before the actual FDA decision. Some traders play the run-up and sell before the decision to avoid the binary risk.
How do hedge funds trade biotech catalysts?
Top biotech hedge funds like Baker Brothers, OrbiMed, and RA Capital approach catalysts by starting with deep scientific analysis, building positions months in advance, sizing based on conviction and risk, diversifying across multiple catalyst events per quarter, and having predefined exit plans. They employ PhDs and former FDA reviewers to analyze drug pipelines at an academic level of detail. You can track their positions using the BiopharmaWatch Hedge Fund Tracker.
When company executives, especially the CEO or Chief Medical Officer, buy shares with their personal money ahead of an FDA decision, it signals confidence in a positive outcome. Insiders have access to non-public information about the clinical data and regulatory interactions that outside investors cannot see. Cluster buying by multiple insiders is the strongest signal, particularly when purchases are large relative to their compensation.
How should I size positions for PDUFA dates?
Position sizing depends on your conviction level. For very high conviction setups (POA 70%+, strong data, hedge fund backing, insider buying), 3% to 5% of your portfolio is reasonable. For moderate conviction, keep it to 0.5% to 1.5%. The key principle is that you should be able to lose the entire position without material damage to your overall portfolio. Professional biotech investors spread their capital across 10 to 20 catalyst events per quarter.
Should I sell before or hold through a PDUFA date?
It depends on your risk tolerance and conviction. Selling before the PDUFA date (playing the run-up) captures 20% to 40% upside without the binary risk of the actual decision. Holding through requires deep conviction based on thorough due diligence and acceptance that a Complete Response Letter could result in a 40% to 80% loss. Many experienced investors do a hybrid: sell part of their position into the run-up and hold the rest through the event.
What is the biggest mistake in biotech catalyst trading?
Oversizing positions. Putting 20% or more of your portfolio into a single PDUFA event is the fastest way to blow up a biotech portfolio. Even the best-researched setups fail 30% to 40% of the time. Professional funds rarely put more than 5% of their portfolio into a single binary event, and most keep it at 1% to 3%. The goal is to survive being wrong so you can keep playing until the math works in your favor.
Where can I track upcoming biotech catalysts?
The BiopharmaWatch FDA Calendar tracks every upcoming PDUFA date, data readout, advisory committee meeting, and NDA/BLA filing across the biotech sector. Each catalyst includes a Probability of Approval score, stage information, and therapeutic area. You can filter by stage, search by ticker, and see what catalysts are coming up this quarter. The Hedge Fund Tracker complements the calendar by showing which institutional investors are positioned for each event.
The Complete Biotech Investing Masterclass
This is Part 4 of 4 in the BiopharmaWatch Biotech Investing Masterclass. Here is the full series:
Part 1: How to Invest in Biotech Stocks covers the fundamentals of biotech investing, the FDA approval process, PDUFA dates, and how to evaluate biotech stocks.
Part 4: Biotech Catalyst Trading (this article) covers how to position around FDA decisions, read hedge fund and insider signals, and avoid the most common catalyst trading mistakes.
Start putting these frameworks into practice today. Visit the BiopharmaWatch FDA Calendar to see what catalysts are coming up this quarter, and use the Hedge Fund Tracker to see what the smart money is doing.
This article is for educational purposes only and does not constitute financial or investment advice. Biotech catalyst trading carries significant risk, including the possibility of total loss on individual positions. Always do your own research and consider consulting a financial advisor before making investment decisions.
Frequently asked questions
What is biotech catalyst trading and why is it important?›
Biotech catalyst trading involves investing in biotech stocks around significant events that can impact their prices, such as FDA decisions or clinical trial results. These catalysts can lead to sharp price movements, making them critical for investors looking to capitalize on potential gains or mitigate risks.
How do hedge funds trade biotech stocks around FDA decisions?›
Hedge funds often employ a disciplined approach to biotech trading, accumulating positions quietly weeks before FDA decisions. They analyze the science behind the drugs and utilize strategies like the PDUFA run-up to maximize returns while managing risks associated with binary events.
What is the PDUFA run-up strategy in biotech investing?›
The PDUFA run-up strategy involves buying biotech stocks 6 to 8 weeks before a PDUFA date and selling 1 to 2 weeks prior to the decision. This strategy aims to capture price appreciation from speculative buying without facing the risks of the actual FDA decision.
What are the risks of insider trading in biotech stocks?›
Insider trading in biotech stocks can lead to significant legal and financial repercussions. While insider buying may indicate confidence in a company's prospects, it can also create ethical dilemmas and regulatory scrutiny, making it essential for investors to approach such information cautiously.
How can I manage risk when trading biotech catalysts?›
Risk management in biotech catalyst trading involves careful position sizing, thorough due diligence, and understanding the potential impacts of binary events. Investors should consider their risk tolerance and develop strategies, such as setting stop-loss orders or diversifying their portfolio, to mitigate potential losses.